Spero Therapeutics (SPRO) Operating Margin (2016 - 2025)
Spero Therapeutics (SPRO) has disclosed Operating Margin for 10 consecutive years, with 135.65% as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Operating Margin rose 239.0% year-over-year to 135.65%, compared with a TTM value of 140.17% through Sep 2025, down 13400.0%, and an annual FY2024 reading of 271.46%, down 257381.0% over the prior year.
- Operating Margin was 135.65% for Q3 2025 at Spero Therapeutics, down from 17.22% in the prior quarter.
- Across five years, Operating Margin topped out at 146.04% in Q4 2022 and bottomed at 12229.55% in Q1 2022.
- Average Operating Margin over 5 years is 2007.86%, with a median of 360.18% recorded in 2021.
- The sharpest move saw Operating Margin skyrocketed 4687128bps in 2021, then plummeted -1196376bps in 2022.
- Year by year, Operating Margin stood at 178.1% in 2021, then skyrocketed by 182bps to 146.04% in 2022, then plummeted by -2232bps to 3113.49% in 2023, then skyrocketed by 91bps to 289.17% in 2024, then skyrocketed by 53bps to 135.65% in 2025.
- Business Quant data shows Operating Margin for SPRO at 135.65% in Q3 2025, 17.22% in Q2 2025, and 250.78% in Q1 2025.